Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
X Bioscience PCLBKK:XBIO FCF Margin % is -59.02% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 360 Restaurants companies, X Bioscience PCL ranks worse than 98.06% on this metric.
The historical data trend for X Bioscience PCL's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:XBIO vs SYY, USFD, PFGC: FCF Margin % Comparison
For the Restaurants subindustry, X Bioscience PCL's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X Bioscience PCL FCF Margin % vs Restaurants Industry
For the Restaurants industry and Consumer Cyclical sector, X Bioscience PCL's FCF Margin % distribution charts can be found below:
* The bar in red indicates where X Bioscience PCL's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X Bioscience PCL (BKK:XBIO) has a FCF Margin % of -59.02% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on X Bioscience PCL and its competitors. According to the industry distribution chart, X Bioscience PCL ranks #353 out of 360 companies in the Restaurants industry, placing it in the top 98.1%.
Is X Bioscience PCL's FCF Margin % too high?
X Bioscience PCL's current FCF Margin % is -59.02%. Based on the distribution chart, X Bioscience PCL ranks #353 out of 360 companies in the Restaurants industry, which is in the bottom quartile relative to peers.
How does X Bioscience PCL's FCF Margin % compare to SYY and USFD?
According to the Restaurants industry distribution chart, X Bioscience PCL ranks #353 out of 360 companies for FCF Margin %. This places X Bioscience PCL in the lower half of its industry. The industry median FCF Margin % is 4.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Restaurants company?
The median FCF Margin % among Restaurants companies is 4.81, based on 360 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on X Bioscience PCL and its competitors. For the Restaurants industry, the median FCF Margin % is 4.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X Bioscience PCL's current FCF Margin % is -59.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X Bioscience PCL stock overvalued right now?
Based on GuruFocus' analysis, X Bioscience PCL (BKK:XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ฿0.10, compared to a current price of ฿0.07 — trading 30% below its estimated fair value. The current FCF Margin % is -59.02%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For X Bioscience PCL (BKK:XBIO), the current FCF Margin % is -59.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X Bioscience PCL, along with its subsidiaries, is mainly engaged in selling food and beverages by operating restaurants and bakery shops under the Le Boeuf, Kagonoya, Bake Cheese Tart, Croquant Chou ZakuZaku, and RAPL trademarks. Additionally, the Group is involved in the production and distribution of biological products. It operates in two business segments: the food and beverage sales segment, which generates maximum revenue, and the production and distribution of biological products segment. Geographically, the Group operates only in Thailand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:XBIO has been successfully added to your 
